Publications by authors named "D Caillot"

Claim this Profile
P
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.
Françoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman, Aurore Perrot, Cyrille Hulin, Denis Caillot

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
Philippe Moreau, Cyrille Hulin, Alexis Talbot, Hélène Demarquette, Léo Caillot, Denis Caillot

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
Sarah Cayla, Lionel Karlin, Jerome Lambert, Anne Lazareth, Alexis Talbot, Denis Caillot

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.
Titouan Cazaubiel, Olivier Decaux, Bruno Royer, Denis Caillot, Arthur Bobin

Clin Hematol Int· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort.
Cyrille Hulin, Karim Belhadj Merzoug, Bruno Royer, Denis Caillot, Arthur Bobin

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis